Lilly buys Alnara for undisclosed sum

Alnara Pharmaceuticals has inked a deal to merge with Eli Lilly for an undisclosed sum. The Cambridge, MA-based developer's lead product is liprotamase, a therapy under FDA review for the treatment of exocrine pancreatic insufficiency. The condition is the result of several diseases, including cystic fibrosis, chronic pancreatitis and pancreatectomy. Alnara says that, if approved, liprotamase will allow many patients to use fewer pills compared with current therapies on the...